Register to receive information about the disease areas of CAH and AI and/or our products that can help to inform your treatment decisions.
By clicking submit you confirm that you agree to receive information and updates from Diurnal Group plc and you accept the terms set out in the privacy policy that can be found on this link: Data privacy statement.
By agreeing to receiving further information, you hereby consent to receive emails which may contain updates on specialist services, conferences, seminars, medical and pharmaceutical promotional materials. We may share your personal information with:
- members of the Diurnal and Neurocrine Biosciences group of companies; and
- the following trusted third parties:
- our agents and suppliers, including those who provide us with technology services such as data analytics, hosting and technical support;
- our professional advisors, auditors and business partners; and
- regulators, governments and law enforcement authorities.
Your personal information may be processed by Diurnal, its affiliated companies and its trusted third-party suppliers outside of your home country. Data privacy laws in the countries to which your personal information is transferred may not be equivalent to, or as protective as, the laws in your home country. We will implement appropriate measures to ensure that your personal information remains protected and secure when it is transferred outside of your home country, in accordance with applicable data protection and privacy laws. These measures include data transfer agreements implementing standard data protection clauses. We are committed to process and use your data only in accordance with the 2018 United Kingdom General Data Protection Regulation (UK-GDPR) legislation.
Code: CORP-EU-0044
Date of Preparation: September 2024